Cholesterol lowering with atorvastatine for the prevention of gallstones following bariatric surgery (CHOLSTONE): an investigator- blinded randomised controlled trial

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524191-38-00

Enrollment

202

Registered

2026-03-17

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gallstones (chole(cysto)lithiasis) following bariatric surgery

Brief summary

Incidence of gallstone formation six months after bariatric surgery, confirmed by ultrasound examination.

Detailed description

Change in plasma LDL-cholesterol levels between baseline and six months after bariatric surgery., Change in fecal and plasma bile acid profiles between baseline and six months after bariatric surgery., Incidence and severity of adverse events related to atorvastatin in the post- bariatric population

Interventions

DRUGATORVASTATIN

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Incidence of gallstone formation six months after bariatric surgery, confirmed by ultrasound examination.	—

Secondary

Measure	Time frame
Change in plasma LDL-cholesterol levels between baseline and six months after bariatric surgery., Change in fecal and plasma bile acid profiles between baseline and six months after bariatric surgery., Incidence and severity of adverse events related to atorvastatin in the post- bariatric population	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 18, 2026